# Successful Re-administration of Granulocyte Colony-Stimulating Factor Without Recurrence of Associated Vasculitis: A Case Report

## TL;DR

A patient with lymphoma experienced a rare side effect from a drug but later safely used it again after the side effect was controlled.

## Contribution

Demonstrates safe re-administration of G-CSF after resolved vasculitis in a lymphoma patient.

## Key findings

- Vasculitis resolved with corticosteroid therapy and did not recur with G-CSF re-administration.
- Successful long-term use of G-CSF after a 14-month interval suggests cautious re-use is possible.
- Findings support individualized management of G-CSF in patients with prior vasculitis.

## Abstract

We report a case of diffuse large B-cell lymphoma complicated by granulocyte colony-stimulating factor (G-CSF)-associated vasculitis following filgrastim administration. The vasculitis resolved with corticosteroid therapy, and maintenance treatment was continued long-term. During salvage chemotherapy for lymphoma relapse 14 months after the initial episode, G-CSF was reintroduced because of persistent myelosuppression. Filgrastim and pegfilgrastim were used in subsequent cycles without recurrence of vasculitis. This case suggests that G-CSF re-administration may be cautiously considered on an individual basis, particularly when vasculitis is well controlled with corticosteroids and a sufficient interval has elapsed. These findings may help guide individualized management in similar clinical situations.